AAV
Market Access/ News/ News/ Press Releases
Solid Biosciences acquires AavantiBio, conducts $75 million private placement
Nicole Raleigh
AAV, aavantbio, acquisition, BAG3, DMD, Duchenne muscular dystrophy, Friedrich's ataxia, gene therapy, M&A, merger, Solid Biosciences
0 Comment
2nd Gene Therapy Immunogenicity
Ellie Saunders
AAV, gene therapy, immunogenicity, Toxicology, virology
0 Comment
Modulate, Measure & Predict Immune Response to GTx
Patients/ R&D/ Views & Analysis/ Views & Analysis/ Views and analysis
‘Knowledge is power’ for rare diseases and NAbs
George Underwood
AAV, Cure Rare Disease, gene therapy, NAbs, Neutralising antibodies, Rare diseases
0 Comment